綠葉制(zhi)藥集(ji)團宣布，其控股子公(gong)司博(bo)(bo)安生(sheng)物(wu)與正大制(zhi)藥(青島)有限(xian)公(gong)司簽署合(he)作協(xie)議，授(shou)予后者骨(gu)(gu)質疏(shu)(shu)松(song)癥治(zhi)療藥物(wu)地(di)舒單抗注射液(ye)(博(bo)(bo)優倍(bei))在(zai)中(zhong)國大陸地(di)區(qu)的獨家(jia)商業(ye)化權利。博(bo)(bo)優倍(bei)由博(bo)(bo)安生(sheng)物(wu)自(zi)主研制(zhi)，于2022年11月在(zai)中(zhong)國獲批上市，用于骨(gu)(gu)折高風險的絕經后婦女的骨(gu)(gu)質疏(shu)(shu)松(song)癥。(醫藥健聞)